Status:
COMPLETED
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization
Lead Sponsor:
UCB Pharma
Conditions:
Partial Seizures With or Without Secondary Generalization
Eligibility:
All Genders
16-70 years
Phase:
PHASE3
Brief Summary
Male and female patients between 16 and 70 years of age who are diagnosed with epilepsy with partial seizures and are taking up to 3 medications for this medical condition will take part in this resea...
Eligibility Criteria
Inclusion
- partial seizures with or without secondary generalization
Exclusion
- subjects received SPM 927 in a previous trial
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
End Date :
January 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00220415
Start Date
May 1 2004
End Date
January 1 2006
Last Update
September 22 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Schwarz
Monheim, Germany